108649-59-8

Basic information

• Product Name: 2 4-DICHLOROPHENETHYL BROMIDE
• Synonyms: 2,4-Dichlorophenethyl broMide 96%;1-(2-Bromoethyl)
• CAS NO: 108649-59-8
• Molecular Formula: C₈H₇BrCl₂
• Molecular Weight: 253.95
• Mol File: 108649-59-8.mol

Chemical Properties

• Boiling Point: 271.622°C at 760 mmHg
• Flash Point: >230 °F
• Appearance: /
• Density: 1.5721 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.011mmHg at 25°C
• Refractive Index: n20/D 1.584(lit.)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2 4-DICHLOROPHENETHYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2 4-DICHLOROPHENETHYL BROMIDE(108649-59-8)
• EPA Substance Registry System: 2 4-DICHLOROPHENETHYL BROMIDE(108649-59-8)

Safety Data

• Hazard Codes: T
• Statements: 25-41
• Safety Statements: 26-39-45
• RIDADR: UN 2810 6.1/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 108649-59-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dichlorophenethyl bromide is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its reactivity allows for the creation of a broad spectrum of medicinal agents, contributing to the development of new treatments and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 2,4-dichlorophenethyl bromide is utilized as a precursor in the production of various agrochemicals. Its role in synthesizing compounds that can be used in pest control and crop protection highlights its importance in ensuring agricultural productivity and food security.
Used in Organic Synthesis:
2,4-Dichlorophenethyl bromide is employed as a key component in organic synthesis processes. Its versatility in undergoing different chemical reactions makes it instrumental in creating a diverse array of organic compounds for various applications, including but not limited to, the development of new materials, dyes, and specialty chemicals.

InChI:InChI=1/C8H7BrCl2/c9-4-3-6-1-2-7(10)5-8(6)11/h1-2,5H,3-4H2

Upstream product

• 81156-68-5 2,4-dichlorophenylethyl alcohol 

Downstream Products

• 1028279-93-7 Thioacetic acid S-[2-(2,4-dichloro-phenyl)-ethyl] ester 
• 711017-43-5 sodium 2-(2,4-dichlorophenyl)ethanesulphonate 
• 129254-90-6 1-(2,4-dichlorophenyl)3-(pyridin-4-yl)-butane 
• 1058856-50-0 C₁₂H₁₄Cl₂O₃ 
• 1327337-56-3 C₁₀H₁₀Cl₂O₃ 
• 1260521-21-8 C₁₀H₈Cl₂O₃ 
• 1355026-31-1 C₁₄H₁₂Cl₂N₂O₃ 
• 1578261-43-4 2,4-dichloro-1-(4-methoxyphenethyl)benzene 
• 61019-61-2 1-(2,4-dichlorophenethyl)-1H-imidazole 
• 1426260-53-8 2-(2,4-dichlorophenethyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-73-2 2-(2,4-dichlorophenethyl)-8-(2,4-dimethoxyphenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1443040-00-3 2,4-dichlorophenylethyl azide 
• 1351938-92-5 1-[2-(2,4-dichlorophenyl)ethyl]-1,2,3,6-tetrahydropyridine hydrochloride 
• 1351938-86-7 1-[2-(2,4-dichlorophenyl)ethyl]-1,2,3,6-tetrahydropyridine 

Relevant articles and documents

BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)

Compounds of formula (I); which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).

PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF MULTIDRUG RESISTANCE

A compound which is a pyrrolopyrimidine of formula (I) wherein: R1 is selected from R9 and halogen; R2 is NR6R7; R3 is selected from H, C1-C6 alkyl which is unsubstituted or substituted and -(CH2) nAr; R4 is selected from H, C1-C6 alkyl and -(CH2)? Ar; or R3 and R4 form, together with the N and C atoms to which they are attached, a fused five-, six-, seven- or eight-membered N-containing saturated ring which is unsubstituted or substituted; R5 is selected from CN, C02R9,C(O)NR10R11, -(CH2)nOH, -(CH2)nR10Rn, -C=CH, -C(S)NR10R11, -C(NH2)=NOR9, -C(R9)=NOR9, -C(NH2)NH, -C(O)R9 and an unsaturated 5- or 6-membered heterocyclic group which contains 1, 2 or 3 heteroatoms selected from N, O and S and which is unsubstituted or substituted; R6 and R7, which are the same or different, are selected from C1-C6 alkyl which is unsubstituted or substituted, -(CH2)nX and -(CH2)nAr; or R6 and R7 form, together with the nitrogen atom to which they are attached, a saturated five-, six-, seven- or eight-membered heterocyclic group which contains one nitrogen atom and 0 or from 1 to 3 additional heteroatoms selected from N, O and S, which is unsubstituted or substituted and which optionally contains one or two bridgehead atoms; R10and R11,which are the same or different, are selected from H, C1-C6 alkyl which is unsubstituted or substituted, -(CH2)nC3-C10 cycloalkyl and -(CH2)nAr; or R10 and R11 form, together with the nitrogen atom to which they are attached, a saturated five or six membered heterocyclic group which contains a nitrogen atom and 0 or from to 3 additional heteroatoms selected from O, S and N, which is unsubstituted or substituted and which is optionally fused to a benzene ring which is unsubstituted or substituted; n is the same or different when more than one is present within a given substituent group and is 0 or an integer of from 1 to 6; X is selected from -CN, -C02R9 and -NR10R11; R9 is the same or different when more than one is present within a given substituent group and is selected from -H, -QAr, -(CH2) nAr, C1-C6 alkyl which is unsubstituted or substituted and -(CH2) nC3-C10cycloalkyl, wherein the cycloalkyl moiety is optionally fused to a benzene ring which is unsubstituted or substituted; Q is C2-C6 alkenylene or alkynylene; and Ar is an unsaturated C6-C10 membered carbocyclic group or an unsaturated 5-11 membered heterocyclic group, which groups are unsubstituted or substituted; or a pharmaceutically acceptable salt thereof. These compounds have activity as inhibitors of MRP (multidrug resistant protein) and may thus be used to modulate multidrug resistance, for instance in potentiating the cytotoxicity of a chemotherapeutic agent.

ATP-citrate lyase as a target for hypolipidemic intervention. Design and synthesis of 2-substituted butanedioic acids as novel, potent inhibitors of the enzyme

ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of 2-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme. The best compounds, 58, 68, 71, 74 have reversible K(i)'s in the 1-3 μM range against the isolated rat enzyme. As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP- citrate lyase.